HTW WHO???????????????
In 2006, Thoratec generated revenue of US$105 million from LVAD
sales. With destination therapy use, the market may potentially
increase to over US$500 million in coming years. Both Throratec
and Ventracor are very well placed, being the two clear leaders in
this market.